ENO1 and acute myeloid leukemia: In order to determine if anti-ENO1 autoantibody levels were predictive of worse disease within the AML cohort, AML patients were stratified into favourable (n = 12), intermediate (n = 3), and adverse (n = 19) risk according to the European LeukemiaNet 2022 classification [24].